Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Q2 2014 Earnings Call July 29, 2014 5:00 pm ET Executives Michael Partridge - Senior Director of Strategic Communications
Vertex Pharmaceuticals ( VRTX ) Q2 results : Total Revenues: $138.4M (-55.5%), Product Sales: $122.3M (-52.0%), Kalydeco Sales: $113
NCR , NEM , NEU , NFX , NTRI , NUVA , PEI , PLT , PNRA , QGEN , RBC , RGR , RKT , RNG , RNR , ROG , RPXC , RT , RUBI , SB , SLCA , SM , SQNM , TMH , TRN , TWTR , TX , UGI , ULTI , USNA , VRSK , VRTX , WNC , WSH , WTS , X , XCO , XPO 1 comment!
By DoctoRx : Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed. Biogen Idec (NASDAQ: BIIB ) fell more than 7% after that statement. Gilead Sciences (NASDAQ: GILD ) fell 5% peak-to-trough. Small ones got dumped big-time. Is it but a passing ...
Vertex Pharmaceuticals ( VRTX ) EVP of Global R&D and Chief Scientific Officer Peter Mueller, Ph.D., announces his retirement effective October 31, 2014, following a planned transition period. Post your comment!
Vertex Pharmaceuticals ( VRTX +1% ) files an sNDA with the FDA for the approval of Kalydeco (ivacaftor) as a treatment for cystic fibrosis (CF) in patients
Medicinal Products for Human Use (CHMP) recommends that the European Medicines Agency (EMA) approve Vertex Pharmaceuticals ' ( VRTX ) Kalydeco ( ivacaftor ) for cystic fibrosis (CF) patients ages six and older who have one of eight non
By DoctoRx: Background : Vertex Pharmaceuticals ( VRTX ) is one of a group of biotech/biopharma companies that focuses on oral medications, not injectable proteins. The company has
This morning Vertex Pharmaceutical ( VRTX ) announced positive results for phase ..... with roughly $20 Million in notional on VRTX . As I wrote in my blog post on binary ..... with two unattractive outcomes - if the VRTX clinical trial was successful, the stock
Top 10 Gainers: VRTX +40% . CRMD +33% . XGTI +32% . KONE +32% . NURO +25% . ISR +18% . MEET +17% . UBIC +16% . INWK +12% . SR +12